Enlarged Prostate (BPH): Symptoms, Causes & Treatment Options

What is an enlarged prostate?

An enlarged prostate, or benign prostatic hyperplasia (BPH), is non-cancerous growth of the prostate gland. The prostate surrounds the urethra, so as it enlarges it can squeeze that channel and obstruct urine flow. BPH is extremely common with age, is not cancer, and does not raise your risk of developing prostate cancer.

The growth occurs specifically in the transition zone — the part of the prostate immediately surrounding the urethra. This is why a relatively modest amount of growth in the wrong place can cause significant symptoms, while some men with very large prostates have almost none.

Two points that surprise many men:

Prostate size and symptom severity correlate poorly. A 40-gram prostate can cause miserable symptoms while a 90-gram prostate causes few. Where the tissue grows matters more than how much of it there is. This is why treatment decisions are driven by how bothered you are, not by a number on an ultrasound.

The bladder is often the real problem. After years of pushing against resistance, the bladder muscle thickens and becomes overactive, then eventually weakens. Some symptoms — particularly urgency and frequency — come from the bladder rather than the prostate, which is why relieving the obstruction does not always resolve everything. The 2026 AUA guideline emphasizes exactly this point: urinary symptoms in men often have multiple contributing causes beyond prostate enlargement alone.

What are the symptoms of an enlarged prostate?

Enlarged prostate symptoms fall into two groups: obstructive symptoms from the blocked channel, and storage symptoms from the bladder’s response. Most men have a mix of both.

Obstructive (voiding) symptoms:

• Weak or slow urinary stream

• Difficulty starting urination, or straining to begin

• Intermittent stream that starts and stops

• Dribbling at the end

• Feeling the bladder has not emptied completely

Storage (irritative) symptoms:

• Urinating frequently during the day

• Waking at night to urinate (nocturia) — often the symptom men find most disruptive

• Sudden, hard-to-defer urgency

• Urge incontinence in more advanced cases

The IPSS: how severity is actually measured

Urologists grade BPH using the International Prostate Symptom Score (IPSS), a seven-question questionnaire scored from 0 to 35, plus a separate quality-of-life question:

Your IPSS, together with how much the symptoms bother you, largely determines the appropriate treatment. It is worth completing one before your appointment — it makes the visit considerably more productive, and it gives you a baseline number to measure improvement against later.

When should I seek urgent care?

Some urinary symptoms need same-day attention rather than a routine appointment. Go to an emergency department or contact a urologist immediately if you experience:

• Complete inability to urinate despite a full, painful bladder (acute urinary retention) — this is a urologic emergency

• Visible blood in the urine, particularly with clots

• Fever, chills, or back or flank pain with urinary symptoms, which may indicate infection reaching the kidneys

• Recurrent urinary tract infections

• Symptoms accompanied by confusion, nausea, or markedly reduced urine output, which can signal kidney involvement

Untreated obstruction can, over time, lead to bladder stones, recurrent infection, bladder damage, and kidney injury. These outcomes are uncommon and largely preventable with treatment, but they are the reason BPH is worth addressing rather than simply tolerating.

Does an enlarged prostate cause prostate cancer?

No. BPH is a benign condition and does not cause prostate cancer or increase your risk of developing it. They are different diseases arising in different parts of the gland — BPH in the transition zone, most cancers in the peripheral zone.

Two related points do matter, though:

They can coexist. Both are common in older men, so having BPH does not protect you from also having prostate cancer. Symptoms alone cannot distinguish them, which is why evaluation includes cancer screening where appropriate.

BPH raises PSA. A larger prostate produces more PSA. This is the single most common cause of an elevated PSA result, and it is why PSA density — PSA relative to prostate volume — helps separate enlargement from cancer.

How is an enlarged prostate diagnosed?

Evaluation establishes three things: how severe your symptoms are, whether the prostate is genuinely the cause, and whether anything else needs ruling out. A typical workup includes:

Core assessment (most men):

• Symptom history and IPSS — the foundation of the evaluation

• Medication review — decongestants, antihistamines, some antidepressants, and diuretics can worsen symptoms or precipitate retention

• Digital rectal exam — estimates size and consistency, and checks for nodules

• Urinalysis — rules out infection, blood, and glucose

• PSA test — where appropriate, since BPH and cancer can coexist and PSA also helps estimate prostate volume

• Post-void residual (PVR) — a quick ultrasound measuring urine left after voiding

Additional testing when indicated:

• Uroflowmetry — measures stream rate objectively

• Transrectal or abdominal ultrasound — measures prostate volume, which directly influences which treatments are suitable

• Cystoscopy — a lighted scope examining the urethra and bladder. Useful before surgery, or when there is blood in the urine or suspicion of stricture or bladder pathology. It is a selective test, not a routine one.

• Urodynamics — reserved for cases where it is unclear whether the bladder or the prostate is the primary problem

• Bladder diary — a simple record of fluid intake and voiding, often more informative than any test

Enlarged prostate treatment options

Treatment escalates in steps, and many men never need to go past the first or second. The right choice depends on symptom severity, prostate size and shape, your other medical conditions, whether you take blood thinners, and — importantly — how you weigh sexual side effects against durability.

1. Watchful waiting and lifestyle changes

For mild symptoms (IPSS under 8) that do not bother you much, monitoring is a legitimate strategy. Practical measures that genuinely help:

• Reduce fluids in the 2–3 hours before bed to cut nighttime waking

• Limit caffeine and alcohol, both of which irritate the bladder and increase urine production

• Double voiding — waiting a moment after urinating and trying again

• Timed voiding and bladder training for urgency

• Review your medications with your doctor, particularly over-the-counter decongestants and antihistamines

• Treat constipation, which worsens urinary symptoms

• Regular physical activity, which is associated with slower BPH progression

2. Medication

To correct a common misconception: BPH medication is not necessarily lifelong. Many men take it for a period and then stop, switch, or move to a procedure — often specifically to get off daily medication. Some men on 5-alpha reductase inhibitors do need to continue to maintain the benefit, but "for the rest of your life" is not an accurate description of BPH drug therapy in general, and it should not deter you from starting.

Alpha blockers — tamsulosin, alfuzosin, silodosin, doxazosin, terazosin. Relax smooth muscle in the prostate and bladder neck. Work within days to weeks. Do not shrink the prostate. Common side effects: dizziness, low blood pressure, and retrograde ejaculation (dry orgasm), which is most frequent with tamsulosin and silodosin and reverses on stopping.

5-alpha reductase inhibitors (5-ARIs) — finasteride, dutasteride. Shrink the prostate by roughly 20–30% over 6–12 months. Effective mainly in men with genuinely larger glands (above about 30–40 mL). Slow to work. Side effects can include reduced libido and erectile difficulty in a minority of men. These drugs halve your PSA — your true value is about double the reported number, which your urologist must know.

Tadalafil 5 mg daily — improves urinary symptoms and erectile function simultaneously. The 2026 AUA guideline expanded support for tadalafil combinations, including for men who want to preserve ejaculatory function.

Combination therapy — an alpha blocker plus a 5-ARI outperforms either alone for men with larger prostates and higher progression risk.

Bladder-directed medications — beta-3 agonists (mirabegron, vibegron) or anticholinergics, added when storage symptoms persist despite adequate treatment of the obstruction.

3. Minimally invasive surgical therapies (MISTs)

This category has expanded substantially and is where most of the recent innovation has happened. These procedures are typically done under light sedation or local anesthesia, often in an office or outpatient setting, with faster recovery and markedly lower rates of sexual side effects than traditional surgery.

UroLift® (prostatic urethral lift) — small permanent implants hold the prostate lobes open rather than removing tissue. No cutting or heating. Rapid recovery, minimal catheter time, and very low rates of ejaculatory dysfunction. Best suited to smaller and moderate prostates. Retreatment rates over time are higher than with tissue-removing procedures.

Rezum® (water vapor therapy) — sterile steam delivered into the prostate causes tissue to shrink over the following weeks. Office-based. Strong sexual function preservation. Requires a catheter for several days and symptom improvement builds over 2–3 months rather than immediately. Clearance has been expanded to substantially larger prostates than when the device launched.

iTind® — a temporary nitinol device placed for about 5–7 days that reshapes the bladder neck and prostatic urethra, then removed. No implant remains.

Optilume® BPH — a drug-coated balloon that dilates the prostatic urethra and delivers paclitaxel to maintain the opening. FDA approved in 2023, with published two-year randomized data.

Prostatic artery embolization (PAE) — performed by an interventional radiologist through a small catheter, blocking blood supply to the prostate so it shrinks. The 2026 AUA guideline upgraded the evidence supporting PAE. Particularly useful for men on blood thinners or those who are poor surgical candidates.

4. Tissue-removing surgical procedures

More definitive and more durable, with correspondingly higher rates of retrograde ejaculation.

Aquablation — robotically guided, image-directed waterjet removal of prostate tissue. No heat, which helps preserve surrounding structures and sexual function. Now supported for prostates up to roughly 150 mL, meaningfully expanding who can have it.

GreenLight™ PVP (photoselective vaporization) — laser energy vaporizes obstructing tissue. Low bleeding risk makes it a reasonable option for men on anticoagulants.

TURP and bipolar/button TURP — transurethral resection remains the long-standing benchmark against which other treatments are measured. Bipolar and vaporization variants reduce bleeding and shorten catheter time compared with the older monopolar technique. Highly effective and durable; retrograde ejaculation is common.

HoLEP / ThuLEP (laser enucleation) — the entire obstructing adenoma is shelled out from the inside. Effective essentially regardless of prostate size, with the lowest long-term retreatment rates of any endoscopic option. Technically demanding, so surgeon experience matters considerably. Retrograde ejaculation is expected in most men.

Simple prostatectomy (open, laparoscopic, or robotic) — reserved for very large prostates, or where bladder stones or diverticula need addressing at the same time.

Comparing BPH procedures

Approximate figures for counseling purposes. Individual results vary substantially, and the right choice depends on your anatomy as much as on these averages.

Will BPH treatment affect my sex life?

This is the question most men actually want answered, and it deserves a direct response rather than reassurance.

Retrograde ejaculation — semen travelling backward into the bladder rather than out — is the most common sexual effect of BPH treatment. It is harmless and does not affect the sensation of orgasm, but it does reduce or eliminate visible ejaculate, and it matters for men who want to father children. Rates vary enormously by procedure: very low with UroLift, Rezum, iTind, and PAE; intermediate with Aquablation; common with TURP, GreenLight, and HoLEP.

Erectile function is generally well preserved across BPH procedures. Rates of new erectile dysfunction after modern treatment are low, and men who take daily tadalafil for BPH often see erections improve.

Medications have their own profile. Tamsulosin and silodosin commonly cause retrograde ejaculation, which reverses when the drug is stopped. 5-ARIs can reduce libido or erectile function in a minority of men.

If preserving ejaculation is a priority for you, say so explicitly at your consultation. It genuinely changes which procedures make sense, and it is a legitimate factor to weigh — not a vanity concern.

Why choose Dr. Samadi

• Board-certified urologist and fellowship-trained urologic oncologist

• Complete BPH evaluation including IPSS assessment, flow testing, prostate volume measurement, and PSA interpretation

• Treatment matched to your anatomy and priorities, rather than to whichever procedure the practice happens to favor

• Second opinions welcome, including review of outside imaging and prior treatment

• Midtown Manhattan office at 485 Madison Avenue, convenient to Grand Central

We accept most major insurance plans; our team will verify your specific coverage before your visit.

Schedule a consultation

If urinary symptoms are disrupting your sleep or your day, they are treatable — and the range of options is wider than most men realize.

Request an Appointment

Office: 485 Madison Avenue, 21st Floor, New York, NY 10022 Phone: (212) 365-5000 Hours: [insert hours]

Sources

• Goueli R, Badlani GH, Welliver C, et al. Management of Lower Urinary Tract Symptoms Attributed to Benign Prostatic Hyperplasia: AUA Guideline (2026), Parts I–III. Journal of Urology, May 2026.

• American Urological Association press release, May 7, 2026: 2026 LUTS/BPH Guideline release.

• National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). Prostate Enlargement (Benign Prostatic Hyperplasia).

• Barry MJ, et al. The American Urological Association symptom index for benign prostatic hyperplasia. Journal of Urology.

This page provides general medical information and is not a substitute for individualized medical advice. Discuss your symptoms and treatment options with a qualified physician.